FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
Name and Address of Reporting Person * Clarke Anthony				2. Issuer Name and Ticker or Trading Symbol ACHIEVE LIFE SCIENCES, INC. [ACHV]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) 19820 NORTH CREEK PARKWAY, SUITE 201			3. Date of Earliest Transaction (Month/Day/Year) 08/01/2017								X Officer (give title below) Other (specify below) President & CSO								
(Street) BOTHELL, WA 98011			4. If Amendment, Date Original Filed(Month/Day/Year) 08/03/2017								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person								
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu							ired, Disposed of, or Beneficially Owned								
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		tion	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)							Ownership Form:		Nature Indirect eneficial wnership		
				(Month)	Day/ I	cai)		ode	V	Amou	nt	(A) or (D)	Price	(IIIsti. 3 a	3 and 4) Direct (or Indir (I) (Instr. 4)		direct (I	nstr. 4)	
Common	Stock		08/01/2017				1	A		550,4: (1)	55	A	(1)	550,455			D		
Common Stock		08/01/2017				1	A		359,30 (2)	05	A	(2)	359,305	5		I	B S	y pouse	
Common Stock 08/0		08/01/2017				1	4		538,93 (3)	58	A	<u>(3)</u>	538,958	58		I	В	y Son	
Common Stock		08/01/2017				1	A		176,4	18	A	<u>(4)</u>	176,418	8		I		icanto imited	
Reminder:	Report on a s	separate line fo	or each class of secu	rities ben	eficiall	y ov	wned		Pers	ons whained i	ho r in th	nis for	m are	not requ	ction of inf lired to res OMB conf	spond unl		SEC 14	74 (9-02)
			Table II -	Derivati (<i>e.g</i> ., put										ly Owned					
1. Title of Derivative Conversion Security (Instr. 3) Price of Derivative Security		3. Transactio Date (Month/Day/	n 3A. Deemed Execution Da any	4.		ion	5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Und Secu	itle and bunt of erlying trities rr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly O Fo So Or	wnership orm of erivative ecurity: irect (D)	Beneficia Ownershi (Instr. 4)		
				(Code	v	(A)	(D)	Date Exe	e rcisable		oiration te	Title	Amount or Number of Shares					

Reporting Owners

			Relationships						
Rep	orting Owner Name / Address	Director	10% Owner	Officer	Other				
19820 N SUITE	Anthony NORTH CREEK PARKWAY 201 ELL, WA 98011	X		President & CSO					

Signatures

Sandra Thomson attorney-	08/11/2017
**Signature of R	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This amended Form 4 is filed to correct the number of common shares received in exchange for 1,532 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was \$4.576 per share, representing a closing price of \$0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
- This amended Form 4 is filed to correct the number of common shares received in exchange for 1,000 common shares of Achieve pursuant to the Merger. On the effective (2) date of the Merger, the closing price of Achieve's common stock was \$4.576 per share, representing a closing price of \$0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- This amended Form 4 is filed to correct the number of common shares received in exchange for 1,500 common shares of Achieve pursuant to the Merger. On the effective (3) date of the Merger, the closing price of Achieve's common stock was \$4.576 per share, representing a closing price of \$0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective (4) date of the Merger, the closing price of Achieve's common stock was \$4.576 per share, representing a closing price of \$0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- (5) The reporting holder is a principal owner of Ricanto Limited.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.